Recruiting

Observational Study

Sponsor:

Boston Children's Hospital

Code:

NCT04712812

Conditions

Hereditary Spastic Paraplegia

SPG47

SPG50

SPG51

SPG52

Eligibility Criteria

Sex: All

Age: 0 - 30

Healthy Volunteers: Accepted

Study Details

Brief summary:

The Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia (HSP) is focused on gathering longitudinal clinical data as well as biological samples (skin and/or blood and/or saliva) from male and female patients, under the age of 30, who exhibited early onset symptoms of HSP with (1) a clinical diagnosis of hereditary spastic paraplegia and (2) the presence of variants in HSP related genes and/or be a relative of a person with such a diagnosis. Currently, the treatment for this disorder is generally symptomatic and available therapies improve quality of life, but are grossly inefficient in slowing the disease progression. Access to the registry information will be limited to the study staff who are responsible for recruitment and maintenance of the registry. We hope that recruitment into the registry for studies will advance knowledge of the causes, clinical course, diagnosis, and treatment of these conditions.

Conditions

Hereditary Spastic Paraplegia

SPG47

SPG50

SPG51

SPG52

Study ID

NCT04712812

Start date

Apr 27, 2020

Status verified date

Mar, 2026

Completion date

Dec 31, 2030

Anticipated

Primary completion date

Dec 31, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0 - 30

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Onset of hereditary spastic paraplegia symptoms before the age of 18 years
  • Under the age of 30 years old
  • Must have a genetically confirmed variant in HSP-related genes and a relative of an individual with a confirmed diagnosis (if applicable).

Exclusion Criteria:

  • Not having such a diagnosis and/or not being related to such individual

Study Design

Enrollment

700 participants

Anticipated

Interventions and Outcome Measures

Arms

Proband with Hereditary Spastic Paraplegia

The study population consists of male and female patients up to the age of 30 years old with a clinical and molecular diagnosis of hereditary spastic paraplegia and/or their family members of interest (if applicable).

Primary outcome measure

  • Establishment of disease spectrum [ Time Frame: Through study completion, an average of 1 year ]
  • Establishment of longitudinal data [ Time Frame: Through study completion, an average of 1 year ]
  • Creation of biorepository [ Time Frame: Through study completion, an average of 1 year ]
  • Creation of patient registry [ Time Frame: Through study completion, an average of 1 year ]

Central Contacts and Locations

Central contacts

Locations

Boston Children's Hospital

Recruiting

Boston, Massachusetts, United States, 02115

Contacts

Principal Investigator:

Darius Ebrahimi-Fakhari, MD, PhD

More Information

Sponsor

Boston Children's Hospital

Last update posted

Mar 18, 2026

Last verified

Mar, 2026

Keywords

  • AP4-HSP
  • AP4
  • SPG
  • AP-4
  • AP-4-HSP
  • Spastic Paraplegia
  • Adapter Protein 4
  • HSP
  • Early onset
  • Early onset HSP

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Boston Children's Hospital on 2026-03-18.